Sugi Predict

Sugi Predict / Targets / EIF4EBP1

EIF4EBP1

Eukaryotic translation initiation factor 4E-binding protein 1 · Q13541 · EIF4EBP1 on Sugi Atlas →

2,745 patent compounds predicted against EIF4EBP1, 1,001 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22866435 SCHEMBL22866435 1.00 20/20
SCHEMBL22866436 SCHEMBL22866436 1.00 20/20
SCHEMBL22866457 SCHEMBL22866457 1.00 20/20
SCHEMBL22866490 SCHEMBL22866490 1.00 20/20
SCHEMBL22866507 SCHEMBL22866507 1.00 20/20
SCHEMBL22866515 SCHEMBL22866515 1.00 20/20
SCHEMBL22866517 SCHEMBL22866517 1.00 20/20
SCHEMBL22866563 SCHEMBL22866563 1.00 20/20
SCHEMBL22866679 SCHEMBL22866679 1.00 20/20
SCHEMBL22866747 SCHEMBL22866747 1.00 20/20
SCHEMBL22866756 SCHEMBL22866756 1.00 20/20
SCHEMBL22866757 SCHEMBL22866757 1.00 20/20
SCHEMBL22866775 SCHEMBL22866775 1.00 20/20
SCHEMBL22866776 SCHEMBL22866776 1.00 20/20
Water Water (SCHEMBL27165018) 1.00 20/20
SCHEMBL28704403 SCHEMBL28704403 1.00 20/20
SCHEMBL28704864 SCHEMBL28704864 1.00 20/20
SCHEMBL28704875 SCHEMBL28704875 1.00 20/20
SCHEMBL28708072 SCHEMBL28708072 1.00 20/20
SCHEMBL28708087 SCHEMBL28708087 1.00 20/20

Clinical trials — most relevant to EIF4EBP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer PHASE3COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis PHASE1/PHASE2COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery PHASE2WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer PHASE1COMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Involvement of the Translation Initiation Factors in Resolution of Inflammation in the Elderly Population nanUNKNOWN
Testing of Micellar Casein, Blended Micellar Casein and Native Whey nanCOMPLETED
The Effects of Whey vs. Collagen on MPS nanCOMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation nanCOMPLETED
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) nanRECRUITING
Prehabilitation in Older People Undergoing Total Hip Replacement nanNOT_YET_RECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a EIF4EBP1 binder may also engage these)

ProteinNameSimilarity
Q60876 — 1.000 Q60876 →
Q62622 — 1.000 Q62622 →
Q0P5A7 — 1.000 Q0P5A7 →
O60516 — 0.993 O60516 →
Q98TT6 — 0.992 Q98TT6 →
Q80VV3 — 0.987 Q80VV3 →
B0BN72 — 0.977 B0BN72 →
Q8K2L8 — 0.976 Q8K2L8 →
Q9UPY6 — 0.975 Q9UPY6 →
E1BTG2 — 0.975 E1BTG2 →
Q5R8Q4 — 0.974 Q5R8Q4 →
P49140 — 0.974 P49140 →
Q8K4S7 — 0.973 Q8K4S7 →
Q921C3 — 0.973 Q921C3 →
Q9DB52 — 0.973 Q9DB52 →
Q8R5H6 — 0.973 Q8R5H6 →
P70445 — 0.973 P70445 →
Q6P6X9 — 0.973 Q6P6X9 →
Q66IV1 — 0.972 Q66IV1 →
Q8VHI6 — 0.972 Q8VHI6 →
Q62925 — 0.972 Q62925 →
Q68EF0 — 0.972 Q68EF0 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.972 landscape →
Q02225 — 0.972 Q02225 →
Q5PQS6 — 0.972 Q5PQS6 →
Q5ZIU1 — 0.972 Q5ZIU1 →
Q3UGS4 — 0.972 Q3UGS4 →
Q92558 — 0.972 Q92558 →
Q9EQM6 — 0.972 Q9EQM6 →
Q3TTA7 — 0.972 Q3TTA7 →